Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs

Published:2017-01-09 Issue:2 Volume:26 Page:161-174
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Mastrodicasa Mark A.¹²,Droege Christopher A.³,Mulhall Aaron M.¹²,Ernst Neil E.³,Panos Ralph J.¹²,Zafar Muhammad A.¹

Affiliation:

1. Division of Pulmonary and Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA

2. Department of Medicine, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH, USA

3. Department of Pharmacy Services, University of Cincinnati Medical Center, Cincinnati, OH, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2017.1276167

Reference58 articles.

1. Tiotropium bromide: A new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease

2. Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends

3. Pharmacologic Characterization of GSK-961081 (TD-5959), a First-in-Class Inhaled Bifunctional Bronchodilator Possessing Muscarinic Receptor Antagonist and β2-Adrenoceptor Agonist Properties

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and synthesis of 2-(2,2-diarylethyl)-cyclamine derivatives as M3 receptor antagonists and functional evaluation on COPD;Bioorganic Chemistry;2023-02

2. Features and significance of the early bronchodilatation effect of the first dose of a long-acting bronchodilator alone and in fixed combination in the treatment of chronic obstructive pulmonary disease;Bulletin of the Russian Military Medical Academy;2022-04-20

3. Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis;Heart & Lung;2022-03

4. Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies;European Journal of Pharmaceutical Sciences;2021-02

5. Emerging muscarinic receptor antagonists for the treatment of asthma;Expert Opinion on Emerging Drugs;2020-04-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3